ORBi: Scherpereel a - Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study

Reference : Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Oncology
	To cite this reference:	http://hdl.handle.net/2268/84988

Title :	Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
Language :	English
Author, co-author :	Scherpereel, a [ > > ]
	Berghmans, t [ > > ]
	Lafitte, j.j [ > > ]
	Colinet, b [ > > ]
	Richez, m [ > > ]
	Bonduelle, y [ > > ]
	Meert, a.p [ > > ]
	Dhalluin, x [ > > ]
	Leclercq, n [ > > ]
	Paesmans, m [ > > ]
	Willems, Luc [Université de Liège - ULg > Chimie et bio-industries > Centre de Bio. Fond. - Section de Biologie cell. et moléc. >]
	Sculier, j.p [ > > ]
Publication date :	Jan-2011
Journal title :	European Respiratory Journal
Publisher :	European Respiratory Society
Volume :	37
Pages :	129-135
Peer reviewed :	Yes (verified by ORBi)
Audience :	International
ISSN :	0903-1936
e-ISSN :	1399-3003
City :	Lausanne
Country :	Switzerland
Keywords :	[en] valproic acid ; doxorubicin ; mesothelioma ; histone deacetylase inhibitors ; Chemotherapy
Abstract :	[en] No treatment is recommended for patients with malignant mesothelioma (MM) failing after first-line cisplatin-based chemotherapy. In vitro data suggested that valproic acid, a histone deacetylase inhibitor (HDACi), had a proapoptotic effect and synergised with doxorubicin to induce apoptosis in MM cells. Our primary end-point was to determine response rate of combined valproic acid and doxorubicin in patients with unresectable MM failing after platinum based chemotherapy. Treatment consisted of doxorubicin (60 mg?m-2) plus valproic acid. An interim analysis for response rate was planned after the first 16 registered patients. All the cases were centrally reviewed. From July 2006 to March 2009, 45 eligible patients with pleural MM were registered. The majority of the patients were male (73%), had a performance status (PS) o80 (76%) and an epithelioid subtype (80%). There were seven partial responses (response rate 16%; 95% CI 3– 25%), all in patients with PS 80–100. The best disease control rate was 36% (95% CI 22–51%). Two toxic deaths were observed (febrile neutropenia and cerebral thrombotic event), both in patients with poor PS (60–70). Valproic acid, an HDACi, plus doxorubicin appeared an effective chemotherapy regimen in good PS (80–100) patients with refractory or recurrent MM, for which no standard therapy was available.
Target :	Researchers ; Professionals ; Students
Permalink :	http://hdl.handle.net/2268/84988
DOI :	10.1183/09031936.00037310

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	2011_ERJ_Scherpereel.pdf		Publisher postprint	315.72 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5